Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
celgosivir + peginterferon alfa-2b
- Development stage
- Unknown
- Lead developer
- METRO
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
Celgosivir + peginterferon alfa-2b is an investigational combination of an oral alpha-glucosidase I inhibitor (celgosivir) and a pegylated interferon used for its antiviral effects (peginterferon alfa-2b). Celgosivir inhibits alpha-glucosidase I, an enzyme required for proper folding of viral glycoproteins, thereby blocking a key host factor necessary for hepatitis C virus (HCV) replication. Peginterferon alfa-2b is a recombinant form of interferon that binds to type I interferon receptors, activating the JAK/STAT pathway to induce innate antiviral responses. The combination has been studied for the treatment of chronic hepatitis C, especially in patients who have not responded to previous therapies.
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)GluI (Endoplasmic reticulum alpha-glucosidase I)
Beyond the preview
Go deeper on celgosivir + peginterferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on celgosivir + peginterferon alfa-2b.